Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 271 results for obesity

  1. When should testing for gestational diabetes take place – in the first or second trimester?

    for women diagnosed with gestational diabetes. However, maternal age and obesity are increasing, and some women (especially those from...

  2. Pulsed-field ablation for atrial fibrillation (IPG806)

    Evidence-based recommendations on pulsed-field ablation for atrial fibrillation. This involves using electric field energy to destroy heart cells that are transmitting abnormal electrical impulses.

  3. Long‑term consequences of planning birth in different settings: What are the long‑term consequences for women and babies of planning birth in different settings?

    Secondary outcomes are impact on attachment between mother and child, obesity in children, autoimmune disease, chronic illness,...

  4. More research is needed on the following key outcomes:

    it is hard to get high-quality images, for example, scoliosis and morbid obesity whether the software works in groups that could...

  5. What is the effectiveness of awake body positioning in improving outcomes for people in hospital with COVID-19 who are not intubated and have higher oxygen needs?

    heart disease, chronic kidney disease, cancer, cerebral vascular disease, obesity) Source guidance details Comes from guidance COVID-19

  6. NICE guidance implementation toolkits

    risk-assessment and smoking support. Overweight and obesity management This toolkit supports applying obesity guidance,...

  7. Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)

    Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment.

  8. FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (HTG682)

    Evidence-based recommendations on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care.

  9. Bladder cancer: diagnosis and management (NG2)

    This guideline covers diagnosing and managing bladder cancer in people 18 and above referred from primary care with suspected bladder cancer, and those with newly diagnosed or recurrent bladder (urothelial carcinoma, adenocarcinoma, squamous-cell carcinoma or small-cell carcinoma) or urethral cancer.

  10. Obesity prevention (CG43)

    This guideline has been updated and replaced by NICE guideline NG246.

  11. The PolySoft hernia patch used with the ONSTEP technique to treat inguinal hernias (MIB9)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Polysoft hernia patch for use with the ONSTEP technique to treat inguinal hernias

  12. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

  13. WoundExpress to manage lower leg wounds (MIB261)

    NICE has developed a medtech innovation briefing (MIB) on WoundExpress to manage lower leg wounds .

  14. Hypertension in adults: diagnosis and management (NG136)

    This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.

  15. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)

    This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer. It does not cover pregnant women.